Keith Biggadike

USPTO Granted Patents = 51 (Patent Applications = 5)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 12 (Patent Applications = 13)

Average Co-Inventor Count = 3.3

ph-index = 12

Forward Citations = 474(Granted Patents)

Forward Citations (Not Self Cited) = 408(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Northolt, GB (1989)
Greenford, GB (1992)
Stevanage, GB (2004)
Stevenage, GB (2000 - 2019)

Company Filing History:

Smithkline Beecham Corporation

Glaxosmithkline Intellectual Property Development Limited

Glaxosmithkline Intellectual Property (no.2) Limited

patents

Years Active: 1989-2019

Loading Chart...

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10450341 - Cyclic di-nucleotides as modulators of STING (2019-10-22),

2. 10202386 - Pyrrolo[3,2-D]pyrimidine derivatives as inducers of human interferon (2019-02-12),

3. 10117873 - 6-amino-purin-8-one compounds (2018-11-06),

4. 10047115 - Cyclic dinucleotides useful for the treatment of inter alia cancer (2018-08-14),

5. 9877968 - 6-amino-purin-8-one compounds (2018-01-30),

6. 9346806 - 6-amino-purin-8-one compounds (2016-05-24),

7. 9233962 - Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases (2016-01-12),

8. 8765772 - Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases (2014-07-01),

9. 8754101 - N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists (2014-06-17),

10. 8178573 - Compounds (2012-05-15),

11. 8067426 - 6-amino-purin-8-one compounds (2011-11-29),

12. 7947727 - Compounds (2011-05-24),

13. 7943651 - Compounds (2011-05-17),

14. 7638508 - Glucocorticosteroid compound having anti-inflammatory activity (2009-12-29),

15. 7629335 - Anti-inflammatory androstane derivative (2009-12-08),

Title: **Keith Biggadike: Innovator in Pharmaceutical Patents**

Introduction

Keith Biggadike, based in Stevenage, GB, is a prominent inventor with a remarkable portfolio of 51 patents. His innovative work primarily focuses on the modulation of immune responses, showcasing the application of his inventions in the pharmaceutical field.

Latest Patents

Among his latest contributions, Biggadike has developed compounds such as cyclic di-nucleotides that serve as modulators of STING (Stimulator of Interferon Genes). These compounds, which include pharmaceutical acceptable salts and their tautomers, are crucial for treating various medical conditions, including inflammation, allergic diseases, autoimmune disorders, infectious diseases, cancer, and enhancing vaccine effectiveness. Another significant invention is the pyrrolo[3,2-D]pyrimidine derivatives, which act as inducers of human interferon. These compounds are instrumental in the prevention and treatment of allergic diseases like allergic rhinitis and asthma, as well as other inflammatory conditions and cancers.

Career Highlights

Keith Biggadike has made significant strides in his career by working with leading pharmaceutical companies, including Glaxo Group Limited and SmithKline Beecham Corporation. His expertise in drug development and patenting has made a considerable impact on the advancement of therapeutic options in the industry.

Collaborations

Throughout his career, Biggadike has collaborated with notable coworkers such as Diane Mary Coe and Steven John Coote. These collaborations have helped foster innovation and brought forth groundbreaking scientific research.

Conclusion

Keith Biggadike exemplifies the spirit of innovation through his numerous patents and contributions to the pharmaceutical sector. His work not only exemplifies his expertise but also highlights the importance of research and development in addressing healthcare challenges.

This text is generated by artificial intelligence and may not be accurate.